Skip to main content

Advertisement

SpringerLink
Log in

The cost utility of solifenacin in the treatment of overactive bladder

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Objectives

Overactive bladder may cause significant discomfort to patients. The standard therapy for overactive bladder includes behavioural therapy and sometimes medication. Recently, a new medication (solifenacin 5 and 10 mg) was developed for treatment of overactive bladder. The objective of this study was to assess the cost utility of solifenacin 5 and 10 mg for overactive bladder.

Methods

We developed a Markov model to estimate the cost per quality adjusted life years (QALY) over a period of 12-months. Model parameters were based on randomized clinical trials for solifenacin 5 and 10 mg. Data on utility scores were taken from the literature.

Results

The incremental cost per QALY for solifenacin 5 mg and solifenacin 10 mg compared with placebo were £17,602 and £24,464 respectively. Sensitivity analyses showed that these results were robust to changes of relevant input data.

Conclusion

Solifenacin 5 and 10 mg are cost-effective treatments in patients with overactive bladder.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cardozo L, Castro-Diaz D, Gittelman M et al (2006) Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. Int Urogynecol J Pelvic Floor Dysfunct 17:512–519. doi:10.1007/s00192-005-0058-6

    Article  PubMed  Google Scholar 

  2. Hennessey A, Robertson NP, Swingler R et al (1999) Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. J Neurol 246:1027–1032. doi:10.1007/s004150050508

    Article  PubMed  CAS  Google Scholar 

  3. Johannesson M, O’Conor RM, Kobelt-Nguyen G et al (1997) Willingness to pay for reduced incontinence symptoms. Br J Urol 80:557–562

    PubMed  CAS  Google Scholar 

  4. Kobelt G, Jonsson L, Mattiasson A (1998) Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodyn 17:599–611. doi :10.1002/(SICI)1520-6777(1998)17:6<599::AID-NAU4>3.0.CO;2-J

  5. Milsom I, Abrams P, Cardozo L, Roberts RG et al (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760–766. doi:10.1046/j.1464-410x.2001.02228.x

    Article  PubMed  CAS  Google Scholar 

  6. Nabi G, Cody JD, Ellis G, Herbison P et al (2006) Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev CD003781

  7. Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13:322–338. doi:10.1177/0272989X9301300409

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

This study was funded by an unrestricted fund of Yamanouchi Europe, The Netherlands.

Author information

Authors and Affiliations

  1. Institute for Medical Technology Assessment, Erasmus MC, PO Box 1738, Rotterdam, 3000 DR, The Netherlands

    Leona Hakkaart, Paul Verboom & Maiwenn J. Al

  2. Goffin Consultancy Ltd, Stelling Minnis, Canterbury, UK

    Richard Phillips

Authors
  1. Leona Hakkaart
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Verboom
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Phillips
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maiwenn J. Al
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leona Hakkaart.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hakkaart, L., Verboom, P., Phillips, R. et al. The cost utility of solifenacin in the treatment of overactive bladder. Int Urol Nephrol 41, 293–298 (2009). https://doi.org/10.1007/s11255-008-9448-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-008-9448-2

Keywords

Search

Navigation